Previous reports have suggested a regulatory role of TIM-3 on the expression of other IC molecules, such as PD-L1 in glioma 43, thus implying that anti-TIM-3 agents could be used to strengthen anti-PD-1 agents. Here, HAVCR2 is linked to central nervous system cancer.